MetP Pharma

MetP Pharma is a private, platform-based biotechnology company focused on revolutionizing drug delivery via the intranasal route. Its core technology combines a proprietary semi-solid gel matrix (Silicum), a single-dose sterile applicator (Lecticula), and a scalable filling technology (Maxima) to enable efficient and targeted delivery of drugs, particularly to the central nervous system. The platform has demonstrated preclinical and clinical proof-of-concept, notably with testosterone, and is now being applied to high-value areas like GLP-1 agonists and other peptides for neurological conditions. MetP operates as both a technology licensor and an internal product developer.

Patented, integrated nasal drug delivery platform consisting of Silicum (semi-solid gel matrix for sustained release), Lecticula (single-dose sterile applicator), and Maxima (scalable filling technology). Designed for systemic and direct nose-to-brain delivery of small molecules and biologics.

The nasal drug delivery space is competitive, with players like OptiNose (approved products) and Impel NeuroPharma focusing on neurology. MetP differentiates with its semi-solid gel formulation for sustained release and its fully integrated, scalable platform specifically designed for challenging biologics and direct CNS targeting.